


CLAIMS

1. A compound represented by formula II or a pharmaceutically acceptable salt thereof,



II

wherein R^{11} is independently selected from the group consisting of hydrogen or C_{1-6} alkyl, wherein the alkyl is optionally substituted with one or more R^{11A}, and each R^{11A} is independently selected from the group consisting of halogen, hydroxy, cyano, or amino;
R^{12} is independently selected from the group consisting of hydrogen, deuterium, halogen, or C_{1-6} alkyl, wherein the alkyl is optionally substituted with one or more R^{12A}, and each R^{12A} is independently selected from the group consisting of halogen, hydroxy, cyano, or amino;
R^{13} is independently selected from the group consisting of hydrogen, deuterium, halogen, cyano, C_{1-6} alkyl, or C_{1-6} alkoxy, wherein the alkyl or alkoxy is optionally substituted with one or more R^{13A}, and each R^{13A} is independently selected from the group consisting of halogen, hydroxy, cyano, or amino;
R^{14} is independently selected from the group consisting of hydrogen or C_{1-6} alkyl;
W is selected from the group consisting of 3 or 4;

L_2 is selected from the group consisting of , , and ;

n1 is selected from the group consisting of integers between 0-4.

2. The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein R^{12} is independently selected from the group consisting of hydrogen or deuterium.












3. The compound or the pharmaceutically acceptable salt thereof according to claim 1 or 2, wherein R^{12} is independently selected from halogen, e.g., fluorine or chlorine; or R^{12} is independently selected from C_{1-6} alkyl, wherein the alkyl is optionally substituted with

one or more R^{12A}, and R^{12A} is as defined in claim 1.







4. The compound or the pharmaceutically acceptable salt thereof according to any of claims 1-3, wherein R^{11} is independently selected from hydrogen.



5. The compound or the pharmaceutically acceptable salt thereof according to any of claims 1-4, wherein R^{13} is independently selected from the group consisting of hydrogen or deuterium.

6. The compound or the pharmaceutically acceptable salt thereof according to any of claims 1-4, wherein R^{13} is independently selected from the group consisting of deuterium or C_{1-6} alkoxy, wherein the alkoxy is optionally substituted with one or more R^{13A}, and R^{13A} is as defined in claim 1; or R^{13} is independently selected from halogen, e.g., fluorine or chlorine.

7. The compound or the pharmaceutically acceptable salt thereof according to any of claims 1-6, wherein L_2 is selected from the group consisting of , , , , , , , , , , and , preferably , , , and .





8. The compound or the pharmaceutically acceptable salt thereof according to claim 1, being selected from the group consisting of:



,

,

,

,

,

,






or .


9. The compound or the pharmaceutically acceptable salt thereof according to claim 1, being selected from the group consisting of:


,

,

,

,



,


,


or


.

10. An isotopically substituted form of the compound or the pharmaceutically acceptable salt thereof according to any of claims 1-9, wherein preferably, the isotopically substituted form is a deuterated form.

11. A pharmaceutical composition, comprising a therapeutically effective amount of at least one of the compound or the pharmaceutically acceptable salt thereof according to any of claims 1-9 or the isotopically substituted form according to claim 10, and a pharmaceutically acceptable excipient.

12. The compound or the pharmaceutically acceptable salt thereof according to any of claims 1-9, or the isotopically substituted form according to claim 10, or the pharmaceutical composition according to claim 11 for use as a medicament.

13. Use of the compound or the pharmaceutically acceptable salt thereof according to any of claims 1-9, or the isotopically substituted form according to claim 10, or the pharmaceutical composition according to claim 11 in the preparation of a medicament for preventing and/or treating a disease or disorder associated with elevated plasma levels of

LP(a).

14. Use of the compound or the pharmaceutically acceptable salt thereof according to any of claims 1-9, or the isotopically substituted form according to claim 10, or the pharmaceutical composition according to claim 11 in the preparation of a medicament for preventing and/or treating a cardiovascular disease.